MA49859A - Immunomodulateurs macrocycliques - Google Patents

Immunomodulateurs macrocycliques

Info

Publication number
MA49859A
MA49859A MA049859A MA49859A MA49859A MA 49859 A MA49859 A MA 49859A MA 049859 A MA049859 A MA 049859A MA 49859 A MA49859 A MA 49859A MA 49859 A MA49859 A MA 49859A
Authority
MA
Morocco
Prior art keywords
immunomodulators
macrocyclic
macrocyclic immunomodulators
Prior art date
Application number
MA049859A
Other languages
English (en)
Inventor
Viengkham Malathong
Jeffrey Mcmahon
Darren J Mcmurtrie
Sreenivas Punna
Howard S Roth
Rajinder Singh
Penglie Zhang
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MA49859A publication Critical patent/MA49859A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA049859A 2017-08-08 2018-08-07 Immunomodulateurs macrocycliques MA49859A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762542694P 2017-08-08 2017-08-08

Publications (1)

Publication Number Publication Date
MA49859A true MA49859A (fr) 2021-04-07

Family

ID=65272535

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049859A MA49859A (fr) 2017-08-08 2018-08-07 Immunomodulateurs macrocycliques

Country Status (10)

Country Link
US (3) US10392405B2 (fr)
EP (1) EP3664793B1 (fr)
JP (1) JP7198269B2 (fr)
KR (1) KR102670486B1 (fr)
CN (1) CN111225665B (fr)
AU (2) AU2018313744C1 (fr)
ES (1) ES2926540T3 (fr)
IL (1) IL272490B (fr)
MA (1) MA49859A (fr)
WO (1) WO2019032547A1 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2928164T3 (es) 2015-10-19 2022-11-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
MD3377488T2 (ro) 2015-11-19 2023-02-28 Incyte Corp Compuși heterociclici ca imunomodulatori
MA44075A (fr) 2015-12-17 2021-05-19 Incyte Corp Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
MY199705A (en) 2015-12-22 2023-11-20 Incyte Corp Heterocyclic compounds as immunomodulators
WO2017192961A1 (fr) 2016-05-06 2017-11-09 Incyte Corporation Composés hétérocycliques utilisés comme immunomodulateurs
WO2017205464A1 (fr) 2016-05-26 2017-11-30 Incyte Corporation Composés hétérocycliques utilisés comme immunomodulateurs
KR102685249B1 (ko) 2016-06-20 2024-07-17 인사이트 코포레이션 면역조절제로서의 복소환식 화합물
KR102401963B1 (ko) 2016-06-27 2022-05-25 케모센트릭스, 인크. 면역조절제 화합물
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
WO2018044783A1 (fr) 2016-08-29 2018-03-08 Incyte Corporation Composés hétérocycliques utilisés comme immunomodulateurs
CA3047991A1 (fr) 2016-12-22 2018-06-28 Incyte Corporation Composes heteroaromatiques bicycliques utilises en tant qu'immunomodulateurs
WO2018119224A1 (fr) 2016-12-22 2018-06-28 Incyte Corporation Dérivés de tétrahydro imidazo[4,5-c]pyridine en tant qu'inducteurs d'internalisation de pd-l1
EP3558989B1 (fr) 2016-12-22 2021-04-14 Incyte Corporation Dérivés de triazolo[1,5-a]pyridine en tant qu'immunomodulateurs
EP3558973B1 (fr) 2016-12-22 2021-09-15 Incyte Corporation Dérivés pyridine utilisés en tant qu'immunomodulateurs
PE20191532A1 (es) 2016-12-22 2019-10-23 Incyte Corp Compuestos heterociclicos como inmunomoduladores
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
MA49701A (fr) 2017-07-28 2020-06-03 Chemocentryx Inc Composés immunomodulateurs
CN111225665B (zh) 2017-08-08 2023-12-08 凯莫森特里克斯股份有限公司 大环免疫调节剂
KR102708681B1 (ko) 2018-02-13 2024-09-26 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
US10568874B2 (en) 2018-02-22 2020-02-25 Chemocentryx, Inc. Indane-amines as PD-L1 antagonists
CA3093851A1 (fr) 2018-03-29 2019-10-03 Arbutus Biopharma Corporation Composes 1,1'-biphenyle substitues, analogues de ceux-ci, et procedes les utilisant
RS64055B1 (sr) 2018-03-30 2023-04-28 Incyte Corp Heterociklična jedinjenja kao imunomodulatori
EP4600247A3 (fr) 2018-04-19 2025-11-19 Gilead Sciences, Inc. Inhibiteurs de pd-1/pd-l1
MD3790877T2 (ro) 2018-05-11 2023-08-31 Incyte Corp Derivați de tetrahidro-imidazo[4,5-c]piridină în calitate de imunomodulatori PD-L1
UA126421C2 (uk) 2018-07-13 2022-09-28 Гіліад Сайєнсіз, Інк. Інгібітори pd-1/pd-l1
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
US11266643B2 (en) 2019-05-15 2022-03-08 Chemocentryx, Inc. Triaryl compounds for treatment of PD-L1 diseases
US11872217B2 (en) 2019-07-10 2024-01-16 Chemocentryx, Inc. Indanes as PD-L1 inhibitors
JP7665593B2 (ja) 2019-08-09 2025-04-21 インサイト・コーポレイション Pd-1/pd-l1阻害剤の塩
AR120109A1 (es) 2019-09-30 2022-02-02 Incyte Corp Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores
CR20220216A (es) 2019-10-16 2023-01-09 Chemocentryx Inc Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
US11713307B2 (en) 2019-10-16 2023-08-01 Chemocentryx, Inc. Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
PE20230407A1 (es) 2019-11-11 2023-03-07 Incyte Corp Sales y formas cristalinas de un inhibidor de pd-1/pd-l1
TW202233616A (zh) 2020-11-06 2022-09-01 美商英塞特公司 用於製備pd-1/pd-l1抑制劑以及其鹽及結晶形式之方法
WO2022099018A1 (fr) 2020-11-06 2022-05-12 Incyte Corporation Procédé de préparation d'un inhibiteur de pd-1/pd-l1
WO2022099075A1 (fr) 2020-11-06 2022-05-12 Incyte Corporation Forme cristalline d'un inhibiteur pd-1/pd-l1
CN116947779B (zh) * 2023-07-13 2025-12-16 南方医科大学 一种环状小分子化合物及其制备方法与应用

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1268002A (en) 1917-09-12 1918-05-28 William M Goodwin Measuring instrument.
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5604294A (en) 1991-09-05 1997-02-18 Luly; Jay R. Macrocyclic immunomodulators
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
EP2402317B1 (fr) 2006-03-31 2013-07-03 Novartis AG Inhibiteur de la DGAT
WO2008008059A1 (fr) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Agents anti-cancer et leurs utilisations
WO2008089307A2 (fr) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Méthodes et compositions utilisés dans le traitement de la douleur, de l'inflammation et du cancer
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
US9308236B2 (en) * 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
US20160084839A1 (en) 2013-04-02 2016-03-24 Marisa Dolled-Filhart Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
ES2642074T3 (es) * 2013-09-04 2017-11-15 Bristol-Myers Squibb Company Compuestos útiles como inmunomoduladores
EP3385257A1 (fr) 2013-09-06 2018-10-10 Aurigene Discovery Technologies Limited Dérivés 1,3,4-oxadiazole et 1,3,4-thiadiazole servant d'immunomodulateurs
CN105814028B (zh) 2013-09-06 2018-02-16 奥瑞基尼探索技术有限公司 作为免疫调节剂的1,2,4‑*二唑衍生物
US9850225B2 (en) * 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
CA2947687C (fr) 2014-05-30 2021-07-06 Ventana Medical Systems, Inc. Analyse multiplexe pour une meilleure determination des scores de tissus tumoraux colores pour pd-l1
AU2016230767A1 (en) 2015-03-10 2017-09-07 Aurigene Discovery Technologies Limited 3-substituted 1,3,4-oxadiazole and thiadiazole compounds as immunomodulators
JP2018507894A (ja) 2015-03-10 2018-03-22 オーリジーン ディスカバリー テクノロジーズ リミテッドAurigene Discovery Technologies Limited 免疫調節剤としての3−置換−1,2,4−オキサジアゾールおよびチアジアゾール化合物
US10745382B2 (en) * 2015-10-15 2020-08-18 Bristol-Myers Squibb Company Compounds useful as immunomodulators
ES2928164T3 (es) * 2015-10-19 2022-11-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
MD3377488T2 (ro) 2015-11-19 2023-02-28 Incyte Corp Compuși heterociclici ca imunomodulatori
MA44075A (fr) 2015-12-17 2021-05-19 Incyte Corp Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
MY199705A (en) 2015-12-22 2023-11-20 Incyte Corp Heterocyclic compounds as immunomodulators
EP3190103A1 (fr) 2016-01-08 2017-07-12 Rijksuniversiteit Groningen Inhibiteurs de l'interaction protéine/protéine pd-1/pd-l1
IL261998B2 (en) 2016-04-07 2023-03-01 Chemocentryx Inc Reducing your burden by giving ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
US10545298B2 (en) 2016-12-21 2020-01-28 Corning Research & Development Corporation Traceable fiber optic cable assembly with illumination structure and tracing optical fibers for carrying light received from a light launch device
WO2017192961A1 (fr) 2016-05-06 2017-11-09 Incyte Corporation Composés hétérocycliques utilisés comme immunomodulateurs
RU2735541C2 (ru) 2016-05-23 2020-11-03 Инститьют Оф Материя Медика, Чайниз Экедеми Оф Медикал Сайенсез Простое эфирное производное никотинилового спирта, получение и фармацевтическая композиция и применения
WO2017205464A1 (fr) 2016-05-26 2017-11-30 Incyte Corporation Composés hétérocycliques utilisés comme immunomodulateurs
KR102685249B1 (ko) 2016-06-20 2024-07-17 인사이트 코포레이션 면역조절제로서의 복소환식 화합물
KR102401963B1 (ko) 2016-06-27 2022-05-25 케모센트릭스, 인크. 면역조절제 화합물
CN105959756B (zh) 2016-06-29 2019-04-02 深圳市九洲电器有限公司 一种自带支架且可充电的机顶盒
EP3483142B1 (fr) 2016-07-05 2025-10-15 Beijing Maxinovel Pharmaceuticals Co., Ltd. Composé aromatique d'acétylène ou d'éthylène, produit intermédiaire, procédé de préparation, composition pharmaceutique et leur utilisation
KR102491992B1 (ko) 2016-07-08 2023-01-25 브리스톨-마이어스 스큅 컴퍼니 면역조정제로서 유용한 1,3-디히드록시-페닐 유도체
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
WO2018044783A1 (fr) 2016-08-29 2018-03-08 Incyte Corporation Composés hétérocycliques utilisés comme immunomodulateurs
US10144706B2 (en) 2016-09-01 2018-12-04 Bristol-Myers Squibb Company Compounds useful as immunomodulators
WO2018045142A1 (fr) 2016-09-02 2018-03-08 Polaris Pharmaceuticals, Inc. Inhibiteurs de points de contrôle de l'immunité, compositions et méthodes associées
WO2018051255A1 (fr) 2016-09-14 2018-03-22 Aurigene Discovery Technologies Limited Composés cycliques substitués de 1,3,4-oxadiazole et thiadiazole utilisés en tant qu'immunomodulateurs
WO2018051254A1 (fr) 2016-09-14 2018-03-22 Aurigene Discovery Technologies Limited Composés cycliques substitués -1, 2, 4-oxadiazole en tant qu'immunomodulateurs
JP7106572B2 (ja) 2016-12-20 2022-07-26 ブリストル-マイヤーズ スクイブ カンパニー 免疫調節剤として有用な化合物
EP3558989B1 (fr) 2016-12-22 2021-04-14 Incyte Corporation Dérivés de triazolo[1,5-a]pyridine en tant qu'immunomodulateurs
WO2018119224A1 (fr) 2016-12-22 2018-06-28 Incyte Corporation Dérivés de tétrahydro imidazo[4,5-c]pyridine en tant qu'inducteurs d'internalisation de pd-l1
PE20191532A1 (es) 2016-12-22 2019-10-23 Incyte Corp Compuestos heterociclicos como inmunomoduladores
CA3047991A1 (fr) 2016-12-22 2018-06-28 Incyte Corporation Composes heteroaromatiques bicycliques utilises en tant qu'immunomodulateurs
EP3558973B1 (fr) 2016-12-22 2021-09-15 Incyte Corporation Dérivés pyridine utilisés en tant qu'immunomodulateurs
US20180177784A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3564237A4 (fr) 2016-12-29 2020-06-10 Shenzhen Chipscreen Biosciences Co., Ltd. Composé d'urée, son procédé de préparation et son application
CN108395443B (zh) 2017-02-04 2021-05-04 广州丹康医药生物有限公司 抑制程序性死亡受体配体1的环状化合物及其用途
JP7150745B2 (ja) 2017-03-27 2022-10-11 ブリストル-マイヤーズ スクイブ カンパニー 免疫調節剤としての置換イソキノリン誘導体
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
TW201841896A (zh) 2017-04-26 2018-12-01 大陸商南京聖和藥業股份有限公司 作為pd—l1抑制劑的雜環類化合物
CN108863963B (zh) 2017-05-08 2022-05-27 南京圣和药物研发有限公司 作为pd-l1抑制剂的杂环类化合物
MA49701A (fr) 2017-07-28 2020-06-03 Chemocentryx Inc Composés immunomodulateurs
CN111225665B (zh) 2017-08-08 2023-12-08 凯莫森特里克斯股份有限公司 大环免疫调节剂
CN109400522B (zh) 2017-08-18 2023-04-28 上海轶诺药业有限公司 一种具有pd-l1抑制活性的化合物、其制备方法及用途
EP3692053A1 (fr) 2017-10-03 2020-08-12 Bristol-Myers Squibb Company Immunomodulateurs
CN109665968B (zh) 2017-10-16 2022-02-22 四川科伦博泰生物医药股份有限公司 并环化合物及其制备方法和用途
CN109678796B (zh) 2017-10-19 2023-01-10 上海长森药业有限公司 Pd-1/pd-l1小分子抑制剂及其制备方法和用途
CN109721527B (zh) 2017-10-27 2024-03-12 广州丹康医药生物有限公司 一种新型抗pd-l1化合物、其应用及含其的组合物
BR112020008851A2 (pt) 2017-11-06 2020-10-20 Jubilant Prodel LLC composto da fórmula i, processo de preparação de compostos da fórmula i, composição farmacêutica, método para o tratamento e/ou prevenção de várias doenças, uso, método para o tratamento de câncer, método de tratamento de câncer e método para o tratamento e/ou prevenção de câncer e doenças infecciosas
WO2019120297A1 (fr) 2017-12-22 2019-06-27 上海海雁医药科技有限公司 Immunomodulateur, son procédé de préparation et son utilisation médicale
EP3733659B1 (fr) 2017-12-29 2023-12-20 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Dérivé de vinyle aromatique ou d'éthyle aromatique, procédé de préparation associé, intermédiaire, composition pharmaceutique et application
JP7214752B2 (ja) 2018-01-23 2023-01-30 ブリストル-マイヤーズ スクイブ カンパニー 免疫調節剤として有用な2,8-ジアシル-2,8-ジアザスピロ[5.5]ウンデカン化合物
ES3035608T3 (en) 2018-02-05 2025-09-05 Abbisko Therapeutics Co Ltd Biaryl derivatives and their pharmaceutical application for the treatment of pd-1/pd-l1 signal pathway-mediated diseases
KR102708681B1 (ko) 2018-02-13 2024-09-26 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
US10568874B2 (en) 2018-02-22 2020-02-25 Chemocentryx, Inc. Indane-amines as PD-L1 antagonists
WO2019169123A1 (fr) 2018-03-01 2019-09-06 Bristol-Myers Squibb Company Composés utiles en tant qu'immunomodulateurs
SG11202008950PA (en) 2018-03-13 2020-10-29 Jubilant Prodel LLC Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
WO2019174533A1 (fr) 2018-03-13 2019-09-19 广东东阳光药业有限公司 Inhibiteur de pd-1/pd-l1 à petites molécules et son utilisation dans des médicaments
RS64055B1 (sr) 2018-03-30 2023-04-28 Incyte Corp Heterociklična jedinjenja kao imunomodulatori
CN111936475B (zh) 2018-04-03 2024-05-10 贝达药业股份有限公司 免疫调节剂及其组合物和制备方法
EP4600247A3 (fr) 2018-04-19 2025-11-19 Gilead Sciences, Inc. Inhibiteurs de pd-1/pd-l1
MD3790877T2 (ro) 2018-05-11 2023-08-31 Incyte Corp Derivați de tetrahidro-imidazo[4,5-c]piridină în calitate de imunomodulatori PD-L1
WO2020011209A1 (fr) 2018-07-11 2020-01-16 上海和誉生物医药科技有限公司 Agent immunosuppresseur, son procédé de préparation et son utilisation pharmaceutique
CN112384500B (zh) 2018-07-12 2024-05-14 贝达药业股份有限公司 免疫调节剂及其组合物和制备方法
UA126421C2 (uk) 2018-07-13 2022-09-28 Гіліад Сайєнсіз, Інк. Інгібітори pd-1/pd-l1
US20210269440A1 (en) 2018-07-19 2021-09-02 Betta Pharmaceuticals Co., Ltd Immunomodulators, compositions and methods thereof
CN112424194B (zh) 2018-07-19 2024-02-06 贝达药业股份有限公司 免疫调节剂及其组合物和制备方法
US20210347785A1 (en) 2018-08-01 2021-11-11 Shanghai Ennovabio Pharmaceuticals Co., Ltd. Preparation and application of aromatic compound having immunoregulatory function
MA53506A (fr) 2018-08-29 2021-07-07 Chemocentryx Inc Méthodes de traitement du cancer avec des inhibiteurs de pd-l1 à petites molécules
CN109336857A (zh) 2018-11-13 2019-02-15 南方医科大学 一种含取代联苯的黄酮及其应用
CN109438263A (zh) 2018-11-28 2019-03-08 南方医科大学 一种含取代联苯的萘及其应用
CN109503546A (zh) 2019-01-10 2019-03-22 南方医科大学 一种间苯二酚二苯甲醚及其应用
CN109776377B (zh) 2019-02-01 2021-08-24 沈阳药科大学 吲哚啉类化合物及其制备方法和应用
CN109776445B (zh) 2019-03-28 2022-12-06 中国药科大学 苯并噁二唑类化合物及其制备方法和医药用途
US11266643B2 (en) 2019-05-15 2022-03-08 Chemocentryx, Inc. Triaryl compounds for treatment of PD-L1 diseases
CN110200959A (zh) 2019-05-30 2019-09-06 天津科技大学 一种黄酮类化合物的应用
CN110128415B (zh) 2019-05-31 2022-03-25 沈阳药科大学 用作免疫调节剂的吲哚啉类化合物及其制备方法
US11872217B2 (en) 2019-07-10 2024-01-16 Chemocentryx, Inc. Indanes as PD-L1 inhibitors
MX2022016554A (es) 2020-06-23 2023-04-10 Chemocentryx Inc Métodos de tratamiento del cáncer mediante derivados heteroaril-bifenil-amida.

Also Published As

Publication number Publication date
AU2023200565B2 (en) 2025-01-02
AU2018313744A1 (en) 2020-02-20
US11691985B2 (en) 2023-07-04
US20220119405A1 (en) 2022-04-21
EP3664793A4 (fr) 2021-04-07
WO2019032547A1 (fr) 2019-02-14
US20190048022A1 (en) 2019-02-14
AU2018313744B2 (en) 2022-11-03
IL272490B (en) 2022-01-01
KR102670486B1 (ko) 2024-05-28
US11059834B2 (en) 2021-07-13
CA3071951A1 (fr) 2019-02-14
US10392405B2 (en) 2019-08-27
AU2023200565A1 (en) 2023-03-02
AU2018313744C1 (en) 2023-07-27
EP3664793A1 (fr) 2020-06-17
EP3664793B1 (fr) 2022-06-29
IL272490A (en) 2020-03-31
CN111225665B (zh) 2023-12-08
JP7198269B2 (ja) 2022-12-28
US20200055869A1 (en) 2020-02-20
JP2020530452A (ja) 2020-10-22
CN111225665A (zh) 2020-06-02
KR20200056989A (ko) 2020-05-25
ES2926540T3 (es) 2022-10-26

Similar Documents

Publication Publication Date Title
EP3664793A4 (fr) Immunomodulateurs macrocycliques
IL261408B (en) Immunomodulators
IL271964A (en) Macrocyclic compounds and uses thereof
EP3488415A4 (fr) Emoji personnalisable
DK3627029T3 (da) Manipulationssikret låg
DK3405050T3 (da) Børnesikret snusbeholder
DK3233887T3 (da) Immunmodulatorer
HUE051659T2 (hu) Makrociklusos peptidek, amelyek hasznosak immunmodulátorokként
BR112016027232A2 (pt) antibióticos macrocíclicos de amplo espectro
DK3504506T3 (da) Mål
DK3436823T3 (da) Antigen-array
DK3335532T3 (da) Tandharve
DK3402792T3 (da) Quinolin-2-on-derivater
CL2015001890S1 (es) Componentes de radio modular
DK3445708T3 (da) Stigbøjle
DK3452590T3 (da) Plademagnet
EP3543552A4 (fr) Éléments de glissement
DK3509963T3 (da) Pallecontainer
DK3528829T3 (da) Bacitracin-alginat-oligomer-konjugater
EP3978758C0 (fr) Compresseur rotatif
DK3575238T3 (da) Pallecontainer
DK3701424T3 (da) Indretning
DE112017000734A5 (de) Glycolsensor
EP3698005A4 (fr) Élargisseur
DE112017006386A5 (de) Schraubarbeitszylinder